SK Biopharmaceuticals signs KRW 63.31 billion drug supply deal with SK Life Science Inc
Bitget2026/09/23 05:50- SK Biopharmaceuticals signed a drug supply contract valued at KRW 63.31 billion to supply cenobamate (XCOPRI) for US sales.
- Counterparty SK Life Science is its US subsidiary, making the deal an internal transaction not recognized as consolidated revenue.
- Contract value reflects USD 46.55 million converted at KRW 1,360 per USD, excluding VAT.
- Order date was Sept. 23, 2026; contract runs Sept. 23-25, 2026; payment due within 120 days of delivery.
- Deal equals 9% of 2025 consolidated revenue of KRW 706.74 billion.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pre-orders for GTA 6 are booming and may reverse the downward trend! Citigroup raises Take-Two Interactive Software (TTWO.US) target to $270
Citigroup maintains a "Buy" rating on Take-Two Interactive Software, with a target price of $270.
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Crypto prices
More
